The biggest Medicare change for weight loss in decades
On December 23, 2025, CMS announced the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model and the Medicare GLP-1 Bridge — a short-term demonstration program providing eligible Medicare Part D beneficiaries with access to GLP-1 medications for weight management. The Bridge launches July 1, 2026, and runs through December 31, 2027. For the first time, Medicare will cover GLP-1 medications specifically for weight loss — not just for diabetes.
The three eligibility tiers
You must meet at least one of these three tiers. Each has different BMI and clinical criteria.
Eligibility Tiers (CMS FAQ, March 2026)
Tier 1 — BMI ≥ 27 with at least one of: pre-diabetes (per ADA guidelines), previous myocardial infarction (heart attack), previous stroke, or symptomatic peripheral artery disease.
Tier 2 — BMI ≥ 30 with at least one of: heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension on 2+ medications, or chronic kidney disease Stage 3a or higher.
Tier 3 — BMI ≥ 35 with no additional conditions required.
Critical detail: when BMI is measured
Your clinical criteria are assessed at the time you first started GLP-1 therapy — not at the time you apply for the Bridge program. This is a crucial distinction. If you started GLP-1 treatment in 2024 with a BMI of 37 and have since lost weight to a BMI of 34, you still qualify under Tier 3 because your BMI was ≥35 when therapy was initiated. Your provider attests to the BMI at treatment initiation.
This also means that beneficiaries who started GLP-1 therapy before enrolling in Medicare Part D, or before the Bridge program launched, can still qualify based on their BMI at the time of treatment initiation.
Covered medications
As of the April 2026 update, three medications are confirmed for coverage under the Medicare GLP-1 Bridge for weight management: Wegovy (semaglutide injection), Zepbound (tirzepatide injection), and additional medications may be announced before the July launch. CMS will release detailed guidance on pharmacy claims procedures ahead of July 1, 2026.
Cost: approximately $50 per month
Eligible beneficiaries under the Bridge program will pay approximately $50 per month for their GLP-1 medication. Compared to retail pricing ($1,000+/mo) or even cash-pay pricing ($349–$499/mo), this represents a dramatic cost reduction for Medicare beneficiaries.
Common misconceptions
Myth: Any Medicare beneficiary can get GLP-1 drugs through this program. Not true — you must be enrolled in an eligible Part D plan and meet the clinical criteria described above.
Myth: The program covers GLP-1s for any use. No — the Bridge covers GLP-1 medications specifically for weight management. If you're prescribed a GLP-1 for a different indication (e.g., Zepbound for obstructive sleep apnea, or Wegovy for cardiovascular risk reduction), that prescription may be covered under different Medicare pathways, not the Bridge specifically.
Myth: Compounded GLP-1 medications are covered. No — the Bridge covers only FDA-approved brand-name medications.
How to prepare
If you think you may qualify, talk to your provider now. Confirm your BMI at the time of GLP-1 treatment initiation (or have them document your current BMI if you haven't started yet). Gather documentation of qualifying comorbidities. Verify your Part D plan will participate in the Bridge program. CMS will provide additional enrollment details before the July 1, 2026 launch.